Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors

The high mortality rate of lung cancer patients is mainly due to the late stage at which lung cancer is diagnosed. For effective cancer prevention programs and early diagnosis, better blood-based markers are needed. Hence, blood-based microarray profiling of microRNA (miR) expression was performed i...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Carina, Stückrath, Isabel, Pantel, Klaus, Izbicki, Jakob R., Tachezy, Michael, Schwarzenbach, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366929/
https://www.ncbi.nlm.nih.gov/pubmed/22675530
http://dx.doi.org/10.1371/journal.pone.0038248
_version_ 1782234789005230080
author Roth, Carina
Stückrath, Isabel
Pantel, Klaus
Izbicki, Jakob R.
Tachezy, Michael
Schwarzenbach, Heidi
author_facet Roth, Carina
Stückrath, Isabel
Pantel, Klaus
Izbicki, Jakob R.
Tachezy, Michael
Schwarzenbach, Heidi
author_sort Roth, Carina
collection PubMed
description The high mortality rate of lung cancer patients is mainly due to the late stage at which lung cancer is diagnosed. For effective cancer prevention programs and early diagnosis, better blood-based markers are needed. Hence, blood-based microarray profiling of microRNA (miR) expression was performed in preoperative serum of 21 non-small cell lung cancer (NSCLC) patients and 11 healthy individuals by microfluid biochips containing 1158 different miRs. Two out of the 30 most dysregulated miRs were further validated in serum of 97 NSCLC patients, 20 patients with benign lung diseases and 30 healthy individuals by TaqMan MicroRNA Assays. Microarray profiling showed that miR-361-3p and miR-625* were significantly down-regulated in serum of lung cancer patients. Their further evaluation by quantitative RT-PCR showed that the levels of miR-361-3p and miR-625* were lower in NSCLC than in benign disease (p = 0.0001) and healthy individuals (p = 0.0001, p = 0.0005, respectively). Moreover, the levels of miR-625* were significantly lower in patients with large cell lung cancer (LCLC, p = 0.014) and smoking patients (p = 0.030) than in patients with adenocarcinoma and non-smoking patients, respectively. A rise in the levels of both miRs was observed in the postoperative samples compared with the preoperative levels (p = 0.0001). Functional analyses showed that Smad2 and TGFß1 are not dysregulated by miR-361-3p and miR-625* in the lung cell line A549, respectively. Our present pilot study suggests that miR-361-3p and miR-625* might have a protective influence on the development of NSCLC, and the quantitative assessment of these miRs in blood serum might have diagnostic potential to detect NSCLC, in particular in smokers.
format Online
Article
Text
id pubmed-3366929
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33669292012-06-06 Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors Roth, Carina Stückrath, Isabel Pantel, Klaus Izbicki, Jakob R. Tachezy, Michael Schwarzenbach, Heidi PLoS One Research Article The high mortality rate of lung cancer patients is mainly due to the late stage at which lung cancer is diagnosed. For effective cancer prevention programs and early diagnosis, better blood-based markers are needed. Hence, blood-based microarray profiling of microRNA (miR) expression was performed in preoperative serum of 21 non-small cell lung cancer (NSCLC) patients and 11 healthy individuals by microfluid biochips containing 1158 different miRs. Two out of the 30 most dysregulated miRs were further validated in serum of 97 NSCLC patients, 20 patients with benign lung diseases and 30 healthy individuals by TaqMan MicroRNA Assays. Microarray profiling showed that miR-361-3p and miR-625* were significantly down-regulated in serum of lung cancer patients. Their further evaluation by quantitative RT-PCR showed that the levels of miR-361-3p and miR-625* were lower in NSCLC than in benign disease (p = 0.0001) and healthy individuals (p = 0.0001, p = 0.0005, respectively). Moreover, the levels of miR-625* were significantly lower in patients with large cell lung cancer (LCLC, p = 0.014) and smoking patients (p = 0.030) than in patients with adenocarcinoma and non-smoking patients, respectively. A rise in the levels of both miRs was observed in the postoperative samples compared with the preoperative levels (p = 0.0001). Functional analyses showed that Smad2 and TGFß1 are not dysregulated by miR-361-3p and miR-625* in the lung cell line A549, respectively. Our present pilot study suggests that miR-361-3p and miR-625* might have a protective influence on the development of NSCLC, and the quantitative assessment of these miRs in blood serum might have diagnostic potential to detect NSCLC, in particular in smokers. Public Library of Science 2012-06-04 /pmc/articles/PMC3366929/ /pubmed/22675530 http://dx.doi.org/10.1371/journal.pone.0038248 Text en Roth et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Roth, Carina
Stückrath, Isabel
Pantel, Klaus
Izbicki, Jakob R.
Tachezy, Michael
Schwarzenbach, Heidi
Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
title Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
title_full Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
title_fullStr Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
title_full_unstemmed Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
title_short Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors
title_sort low levels of cell-free circulating mir-361-3p and mir-625* as blood-based markers for discriminating malignant from benign lung tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366929/
https://www.ncbi.nlm.nih.gov/pubmed/22675530
http://dx.doi.org/10.1371/journal.pone.0038248
work_keys_str_mv AT rothcarina lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors
AT stuckrathisabel lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors
AT pantelklaus lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors
AT izbickijakobr lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors
AT tachezymichael lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors
AT schwarzenbachheidi lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors